

## LBA5000

CABAZITAXEL WITH ABIRATERONE VERSUS ABIRATERONE ALONE RANDOMIZED TRIAL FOR EXTENSIVE DISEASE FOLLOWING DOCETAXEL: THE CHARTED2 TRIAL OF THE ECOG-ACRIN GROUP

## 5001

CYCLONE 2: A PHASE 3 STUDY OF ABEMACICLIB WITH ABIRATERONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER.

## 5003

HEALTH-RELATED QUALITY OF LIFE AND PAIN IN A PHASE 3 STUDY OF [177LU]LU-PSMA-617 IN TAXANE-NAÏVE PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (PSMAFORE).

## 5005

EMBARC POST HOC ANALYSIS OF IMPACT OF TREATMENT SUSPENSION (TXS) ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)

## 5006

HEALTH-RELATED QUALITY OF LIFE (HRQOL) RESULTS FROM PRESTO (AFT-19), A PHASE 3 RANDOMIZED TRIAL OF INTENSIFICATION OF ANDROGEN BLOCKADE IN PATIENTS WITH HIGH-RISK BIOCHEMICALLY RELAPSED CASTRATION SENSITIVE PROSTATE CANCER.

## 5007

A CLINICAL-GENETIC (CG) CIRCULATING TUMOR DNA (CTDNA)-BASED PROGNOSTIC MODEL FOR PREDICTING OVERALL SURVIVAL (OS) IN MEN WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC) TREATED WITH POTENT ANDROGEN RECEPTOR INHIBITION (ALLIANCE).

## 5008

BASELINE CTDNA ANALYSES AND ASSOCIATIONS WITH OUTCOMES IN TAXANE-NAIVE MCRPC TREATED WITH 177LU-PSMA-617 VERSUS CHANGE OF ARPI IN PSMAFORE.

## 5020

UTILITY OF CTDNA BURDEN AS A PROGNOSTIC BIOMARKER FOR EFFICACY IN TALAPRO-2: A PHASE 3 STUDY OF TALAZOPARIB (TALA) + ENZALUTAMIDE VS PLACEBO + ENZA AS FIRST-LINE TREATMENT IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

## 5078


TREATMENT OUTCOMES FOR PATIENTS WITH GA68-PSMA-PET PROSTATE CANCER (PC) WITH OR WITHOUT CONVENTIONAL IMAGING CORRELATES.

## 5015

CLINICAL UTILITY OF TRANSCRIPTOMIC SIGNATURES TO IDENTIFY ANDROGEN RECEPTOR AND NEUROENDOCRINE SIGNALING IN PROSTATE CANCER.

Leads

Faculty



**4502**

PATIENT-REPORTED OUTCOMES (PROS) FROM A RANDOMIZED, PHASE 3 TRIAL OF ENFORTUMAB VEDOTIN PLUS PEMBROLIZUMAB (EV+P) VERSUS PLATINUM-BASED CHEMOTHERAPY (PBC) IN PREVIOUSLY UNTREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER (LA/MUC).

**4511**

CAMRELIZUMAB PLUS APATINIB FOR PREVIOUSLY TREATED ADVANCED ADRENOCORTICAL CARCINOMA: A SINGLE-ARM, OPEN-LABEL, PHASE 2 TRIAL.

**5009**

A PHASE II TRIAL OF PEMBROLIZUMAB PLUS PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE SYSTEMIC THERAPY IN ADVANCED PENILE CANCER: **HERCULES** (LACOG 0218) TRIAL.

**4506**

CIRCULATING KIDNEY INJURY MOLECULE-1 (KIM-1) BIOMARKER ANALYSIS IN **IMMOTION010**: A RANDOMIZED PHASE 3 STUDY OF ADJUVANT (ADJ) ATEZOLIZUMAB (ATEZO) VS PLACEBO (PBO) IN PATIENTS WITH RENAL CELL CARCINOMA AT INCREASED RISK OF RECURRENCE AFTER RESECTION.

**4516**

AVELUMAB (A) AS NEOADJUVANT THERAPY IN PATIENTS (PTS) WITH MUSCLE-INVASIVE UROTHELIAL CARCINOMA (MIUC): SURVIVAL DATA OF AURA TRIAL, ONCODISTINCT 004.

**4505**

BIOMARKER ANALYSIS OF THE PHASE 3 KEYNOTE-426 STUDY OF PEMBROLIZUMAB (P) PLUS AXITINIB (A) VERSUS SUNITINIB (S) FOR ADVANCED RENAL CELL CARCINOMA (RCC).

**4517**

PERIOPERATIVE SACITUZUMAB GOVITECAN (SG) ALONE OR IN COMBINATION WITH PEMBROLIZUMAB (PEMBRO) FOR PATIENTS WITH MUSCLE-INVASIVE UROTHELIAL BLADDER CANCER (MIBC): **SURE-01/02** INTERIM RESULTS.

**4510**

A MULTICENTER PHASE II STUDY OF MODIFIED FOLFIRINOX FOR FIRST-LINE TREATMENT FOR ADVANCED URACHAL CANCER (**ULTMA; KCSG GU20-03**)

**4518**

QUANTITATIVE CIRCULATING TUMOR DNA (CTDNA) ASSESSMENT IN PATIENTS (PTS) WITH ADVANCED UROTHELIAL CARCINOMA (UC) TREATED WITH PEMBROLIZUMAB (PEMBRO) OR PLATINUM-BASED CHEMOTHERAPY (CHEMO) FROM THE PHASE 3 **KEYNOTE-361** TRIAL.

**4503**

IMPACT OF EXPOSURE ON OUTCOMES WITH ENFORTUMAB VEDOTIN IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER.

Leads

Faculty



Dr Yekeduz  
Med Onc



Dr Gandur  
Med Onc



Dr Morgan  
Clin Onc



Dr Choueiri  
Med Onc



Dr Apolo  
Med Onc




Dr Grivas  
Med Onc



Dr Grande  
Med Onc



Dr Zhang  
Med Onc



Dr Pal  
Med Onc



Dr Heng  
Med Onc



Dr Agarwal  
Med Onc



Dr Efstathiou  
Med Onc



Dr Castellano  
Med Onc



Dr Urun  
Med Onc